Pages that link to "Q6482030"
Jump to navigation
Jump to search
The following pages link to lamivudine/zidovudine (Q6482030):
Displaying 45 items.
- HIV/AIDS (Q12199) (← links)
- World Health Organization Model List of Essential Medicines (Q37155) (← links)
- The renaissance of fixed dose combinations: Combivir (Q28279752) (← links)
- Combivir (Q29005653) (← links)
- Lamivudine/zidovudine Teva (Q29006107) (← links)
- Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. (Q34781913) (← links)
- Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers (Q36558235) (← links)
- Tropical spastic paraparesis treated with Combivir (lamivudine-zidovudine). (Q39054056) (← links)
- Synergistic antivirus effect of combined administration of Combivir with Angelica polysaccharide sulfate (Q39244322) (← links)
- Low Third-Trimester Serum Levels of Lamivudine/Zidovudine and Lopinavir/Ritonavir in an HIV-Infected Pregnant Woman with Gastric Bypass (Q41681837) (← links)
- Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). (Q42631799) (← links)
- Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients (Q43662791) (← links)
- Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment (Q43699699) (← links)
- The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects (Q43904174) (← links)
- Counterfit drugs: check Combivir, Serostim, Epogen. (Q44042479) (← links)
- Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne (Q44190456) (← links)
- Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults (Q44547871) (← links)
- Comparison of generic zidovudine + lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets (Q44799930) (← links)
- Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir containing regimen (Q44805807) (← links)
- Response to the comparison of generic zidovudine plus lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets (Q45189070) (← links)
- Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. (Q45915490) (← links)
- Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia (Q46593290) (← links)
- Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects (Q50122562) (← links)
- Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. (Q51563075) (← links)
- Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. (Q53912257) (← links)
- FDA notifications. FDA tentatively approves fixed-dose lamivudine/zidovudine (Q56898388) (← links)
- FDA notifications. Lamivudine/zidovudine combination approved for pediatric use (Q56901256) (← links)
- FDA notifications. Lamivudine/zidovudine tab tentatively approved (Q56901518) (← links)
- FDA notifications. Generic lamivudine/zidovudine approved (Q56901524) (← links)
- Switching Combivir to Truvada keeps HIV undetectable, improves blood fats, fails to improve limb fat (Q56903828) (← links)
- FDA notifications. FDA approval for generic lamivudine/zidovudine (Q56906629) (← links)
- FDA notifications. Tentative approval for generic lamivudine/zidovudine (Q56907695) (← links)
- FDA notifications. Product tampering labels Ziagen as Combivir (Q56936750) (← links)
- What you need to know about Combivir (Q56961439) (← links)
- Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection (Q57181637) (← links)
- Immune and virologic responses to Truvada or Combivir as a first-line therapy of HIV-infected, treatment-naïve patients (Q59216983) (← links)
- A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION S (Q59249401) (← links)
- Tenofovir regimen compared with Combivir (Q81380565) (← links)
- Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women (Q83369592) (← links)
- Lamivudine/zidovudine: paediatric indication. For certain HIV-infected children (Q83776374) (← links)
- Simple thin layer chromatography-ultraviolet spectrophotometric method for quality assessment of binary fixed-dose-combinations of lamivudine/tenofovir disoproxil fumarate and lamivudine/zidovudine in tablet formulations (Q89995829) (← links)
- Wikidata:Database reports/Constraint violations/P233 (← links | edit)
- Wikidata:Database reports/Constraint violations/P661 (← links | edit)
- Wikidata:Database reports/Constraint violations/P2017 (← links | edit)
- Wikidata:Database reports/Constraint violations/P11089 (← links | edit)